On Tuesday, Kestra Medical Techs received a positive adjustment to its Relative Strength (RS) Rating, from 85 to 92.
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against all other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating north of 80 as they begin their biggest runs.
How To Use Stock Charts To Stay Profitable And Protected
While now is not an ideal time to buy shares, see if the stock is able to offer and clear a proper buy point.
Kestra Medical Techs showed 0% earnings growth in the latest quarterly report. Revenue increased 193%. The next quarterly results are expected on or around Apr. 2.
Kestra Medical Techs earns the No. 31 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
